News from the Vienna Airway Lab 🔬 Dupilumab doesn't just control CRSwNP — it reduces the need for other medications over time. Great work by first author Karina!

Watch her explain it herself: instagram.com/viairlab
and read the paper: pubmed.ncbi.nlm.nih.gov/41853844/

#CRSwNP #Dupilumab #Rhinology

Fundamental & Clinical Pharmacology: Vol 40, No 2 Click on the title to browse this issue

March issue now available!
#fundamental #clinical #pharmacology #statin #pharmacovigilance #addictovigilance #cannabis #ambroxol #dupilumab #buscopan #inflammation #cytokine #SGLT2i #heart #drug #repositioning #antinociceptive #SFPT @wileyhealth.bsky.social
onlinelibrary.wiley.com/toc/14728206...

Dupilumab in Patients With Chronic Spontaneous Urticaria This phase 3 randomized clinical trial re-evaluates the efficacy and safety of dupilumab vs placebo in anti-IgE–naive patients with chronic spontaneous urticaria uncontrolled by histamine 1–receptor a...

Dupilumab reduce la actividad de la urticaria en pacientes con urticaria crónica espontánea naïves a anti-IgE que no se controlan con antihistamínicos, reduciendo el prurito y la gravedad del picor #CSU #dupilumab jamanetwork.com/journals/jam...

FDA Approves Dupilumab for AFRS in Patients Aged ≥ 6 Years With Prior Surgery | HCPLive FDA approves dupilumab for allergic fungal rhinosinusitis, supported by phase 3 LIBERTY-AFRS-AIMS data showing reduced symptoms and corticosteroid or surgery use.

@SanofiUS & @Regeneron announced this morning that the FDA has approved #dupilumab (Dupixent) for allergic fungal rhinosinusitis in patients ≥6 years with prior surgery. Read more here: www.hcplive.com/view... D30

New Research Shows Asthma Biologics Do Not Increase Infection Risks, Offers Hope to Patients Recent research indicates that asthma biologics might not increase the risk of respiratory infections while potentially lowering pneumonia rates. This is encouraging news.

New Research Shows Asthma Biologics Do Not Increase Infection Risks, Offers Hope to Patients #United_States #Philadelphia #AAAAI #Dupilumab #Asthma_Biologics

リジェネロン、AAAAI 2026で免疫領域36演題発表へ──猫・シラカバ花粉アレルギー第3相データ初公開、デュピルマブ新解析も提示 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

リジェネロン、AAAAI 2026で免疫領域36演題発表へ
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI 2026

stellanews.life/technology/8...

AI impact rating（reference only）: ★★★★☆
This is an experimental indicator and not a guarantee of accuracy.

#AAAAI #Allergy #Dupilumab #Phase3 #Regeneron

Cattani (Sanofi): "Con Bpco diventano 11 le indicazioni per dupilumab" (Adnkronos) - "E' un momento di grande soddisfazione, perché la ricerca e sviluppo legata a dupilumab raggiunge il picco più alto. Questa nuova indicazione" nella broncopneumopatia cronica ostruttiva (Bpco), che "sarà approvata a bre...

TI POTREBBE INTERESSARE: Cattani (Sanofi): "Con Bpco diventano 11 le indicazioni per dupilumab" ... LEGGI TUTTO #Sanofi #dupilumab #Bpco #ricerca #salute

Cattani (Sanofi): "Con Bpco diventano 11 le indicazioni per dupilumab" (Adnkronos) - "E' un momento di grande soddisfazione, perché la ricerca e sviluppo legata a dupilumab raggiunge il picco più alto. Questa nuova indicazione" nella broncopneumopatia cronica ostruttiva (Bpco), che "sarà approvata a bre...

È ACCADUTO IERI: Cattani (Sanofi): "Con Bpco diventano 11 le indicazioni per dupilumab" ... LEGGI TUTTO #Sanofi #Dupilumab #Bpco #Salute #Ricerca

Cattani (Sanofi): "Con Bpco diventano 11 le indicazioni per dupilumab" (Adnkronos) - "E' un momento di grande soddisfazione, perché la ricerca e sviluppo legata a dupilumab raggiunge il picco più alto. Questa nuova indicazione" nella broncopneumopatia cronica ostruttiva (Bpco), che "sarà approvata a bre...

Cattani (Sanofi): "Con Bpco diventano 11 le indicazioni per dupilumab" ... LEGGI TUTTO #Sanofi #Bpco #Dupilumab #RicercaMedica #Salute

COPD patients will get access to Dupixent via NHS Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.

#COPDpatients #Dupixent #dupilumab #NHS #chronicobstructivepulmonarydisease #COPD #biologics #Sanofi #Regeneron #uncontrolledCOPD #lungdisease #COPDtherapies #NICEfinaldraftguidance #COPDflareups #COPDdiagnosis #NICE #NHScostsavings #uncontrolledCOPD #COPDcare
zurl.co/7i5io

In this systematic review and meta-analysis, De Vriese et al. report significant geographical differences in dupilumab treatment outcomes as measured by the percentage #eczema area severity index (EASI) and the presence of adverse events (AEs).

Free Access: Geographic Differences in #Dupilumab Treatment Outcomes for #AtopicDermatitis: A Systematic Review and Meta-Regression Analysis. Corresponding author: Inge Kortekaas Krohn
👉 doi.org/10.1111/all.70144

#Allergy_journal
Read more 👉journalallergy.com/Allergen-Specific-Immunotherapy

Synapse: Your Connection to our MSK Authors
Meet: Jennifer Defazio
Research Focus: Medicine; Associate Attending

Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: A retrospective case series
synapse.mskcc.org/synapse/work...

#ImmunoOncology #Dupilumab

🎉 Our new study maps the real-time inflammatory dynamics 🔥of aspirin challenge in N-ERD patients. We further reveal the direct modulatory effect of #dupilumab 💊 on these acute reactions for the first time! 🧪 @cea01.bsky.social

#asthma #CRSwNP #Immunology #Type2Inflammation

🔗 ino.to/7UpJJqA

Vacunación frente a #rotavirus en #lactante que precisa #dupilumab por #dermatitis atópica grave.

📌Se sugiere esperar al menos 4 semanas antes de iniciar el tratamiento con dupilumab
📌Iniciarlo antes podría ser seguro

#Preevid #vacunas

👉👉https://www.murciasalud.es/preevid/26604

“Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps This study aimed to evaluate the feasibility of extending dupilumab dosing intervals in T2-CRSwNP by assessing how many patients maintain disease control with once-every-12-weeks (Q12W) dosing and co....

A new study finds that some patients on #dupilumab for chronic rhinosinusitis with nasal polyps are "super-responders", successfully maintaining disease control with a single dose 💊 just once every 12 weeks.

#CRSwNP #biologics #type2disease #Immunology

🔗 ino.to/WtzjQlV

A New Hope for Kids with Peanut Allergies: Dupilumab and OIT Together

Read more: onlinelibrary.wiley.com/doi/10.1111/...

#PeanutAllergy #Dupilumab #OIT #AllergyResearch #ChildHealth

Dupilumab in Children Under 6 Years With Moderate‐to‐Severe Atopic Dermatitis: A 16‐Week Real‐World Prospective Study on Efficacy, Safety, and Local‐Systemic Immune Responses Sixteen-week dupilumab improved clinical outcomes in young children with AD, restoring skin barrier and suppressing local Th2 inflammation. However, persistent systemic inflammation suggests a need f...

A 16-week #dupilumab 💊 regimen for young kids with eczema restored skin barrier and suppressed local Th2 inflammation 🔥, with machine learning pinpointing new redox-related treatment targets 🎉
#Immunology #biologics #type2immunity #redox #ML

🔗 ino.to/2rLyiTE

Does Dupilumab work for peanut allergies?

#FoodAllergy #PeanutAllergy #Dupilumab #AllergyTreatment #Parenting #HealthResearch #PeanutAllergyAwareness

A study has shown that adding dupilumab to peanut oral immunotherapy (OIT) can help more children build tolerance to peanuts, offering a boost in managing peanut allergies.
doi: 10.1111/all.16420

#PeanutAllergy #OIT #Dupilumab #AllergyAwareness #FamilyHealth #FoodAllergy

Bio-Thera Solutions and SteinCares Join Forces to Bring Biosimilars to Latin America Bio-Thera Solutions partners with SteinCares to offer cost-effective biosimilars for inflammatory diseases, enhancing healthcare access in Latin America.

Bio-Thera Solutions and SteinCares Join Forces to Bring Biosimilars to Latin America #San_Jose #Costa_Rica #SteinCares #Bio-Thera_Solutions #Dupilumab

Dupilumab for Atopic Dermatitis Linked to Increased Risk of Psoriasis These findings must be weighed against the drug's established efficacy in this disease

"This paradoxical reaction highlights the need for increased clinical awareness when evaluating new-onset psoriasiform lesions in patients receiving dupilumab." -- Shoshana Marmon, MD, PhD, on increased #psoriasis risk associated with using #dupilumab for AD.
www.medpagetoday.com/dermatology/...

Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a real-life study - Drugs in Context The objective of this study performed in Brazil was to understand the real-life efficacy and safety of using dupilumab in patients with moderate or severe atopic dermatitis.

📣 New in @drugsincontext.bsky.social

Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a real-life study

Morandin Lopes et al.

#MedSky #PharmSky #dermatology #atopicdermatitis #dupilumab #reallifestudy

www.drugsincontext.com/efficacy-and...

From the May 2025 issue: Seeing red because of #dupilumab associated conjunctivitis? Using metabolomics and lipidomic analysis to understand why ow.ly/uAlc50VoOXQ #medderm #dermsky

Chronic Pruritus Market Set for Significant Growth with Emerging Therapies and Innovative Treatments The chronic pruritus market is projected to experience a robust CAGR of 8.6% between 2020 and 2034, driven by innovative therapies like Dupilumab and others.

Chronic Pruritus Market Set for Significant Growth with Emerging Therapies and Innovative Treatments #None #Chronic_Pruritus #Dupilumab #Linerixibat

Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial The full results of this study indicate that dupilumab reduced airway inflammation and mucus plugging, and improved airway volume and flow, corresponding to improved lung function and asthma control. ...

#Asthma is characterised by chronic airway inflammation & mucus hypersecretion.

Phase 4 trial, VESTIGE, investigated the effect of #dupilumab in patients with type 2 asthma.

More here ⤵️
tinyurl.com/yp3t7jsv #WorldAsthmaDay @lancetrespirmed.bsky.social

New study finds SLC27A2/FATP2-mediated lipid peroxidation drives inflammation in chronic rhinosinusitis with nasal polyps (#CRSwNP), with #dupilumab reducing this pathway and FATP2 inhibition offering a potential therapeutic target.
ino.to/rxGOvVi

#Immunology
#ImmunoSky

Neue Indikation: Dupilumab (DUPIXENT) inzwischen auch bei COPD Dupilumab, das erste Biologikum zur Zusatztherapie bei COPD - was sagen die Daten?

Neue Indikation: #Dupilumab (DUPIXENT) inzwischen auch bei #COPD
Dupilumab, das erste Biologikum zur Zusatztherapie bei COPD - was sagen die Daten?
www.arznei-telegramm.de/html/2025_03...